{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,27]],"date-time":"2026-10-27T16:19:53Z","timestamp":1793117993399,"version":"4.5.0"},"reference-count":150,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2026,4,1]],"date-time":"2026-04-01T00:00:00Z","timestamp":1775001600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,4,1]],"date-time":"2026-04-01T00:00:00Z","timestamp":1775001600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,4,1]],"date-time":"2026-04-01T00:00:00Z","timestamp":1775001600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2026,4,1]],"date-time":"2026-04-01T00:00:00Z","timestamp":1775001600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2026,4,1]],"date-time":"2026-04-01T00:00:00Z","timestamp":1775001600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2026,4,1]],"date-time":"2026-04-01T00:00:00Z","timestamp":1775001600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2026,4,1]],"date-time":"2026-04-01T00:00:00Z","timestamp":1775001600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"funder":[{"DOI":"10.13039\/100016834","name":"Chongqing Municipal Health Commission","doi-asserted-by":"publisher","award":["2024WSJK028"],"award-info":[{"award-number":["2024WSJK028"]}],"id":[{"id":"10.13039\/100016834","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Biochemical Pharmacology"],"published-print":{"date-parts":[[2026,4]]},"DOI":"10.1016\/j.bcp.2026.117724","type":"journal-article","created":{"date-parts":[[2026,1,20]],"date-time":"2026-01-20T17:14:43Z","timestamp":1768929283000},"page":"117724","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":5,"special_numbering":"C","title":["Unraveling the glioblastoma (GBM) tumor microenvironment: future perspective on targeted immunotherapy"],"prefix":"10.1016","volume":"246","author":[{"given":"Jia","family":"Li","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Abdulkareem Qasem","family":"Moqbel","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yongzhao","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Erhu","family":"Zhao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Muhammad Usman","family":"Ghani","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7409-9504","authenticated-orcid":false,"given":"Ping","family":"Liang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"8","key":"10.1016\/j.bcp.2026.117724_b0005","doi-asserted-by":"crossref","first-page":"1073","DOI":"10.1093\/neuonc\/noaa106","article-title":"Glioblastoma in adults: a Society for Neuro-Oncology (SNO) and European Society of Neuro-Oncology (EANO) consensus review on current management and future directions","volume":"22","author":"Wen","year":"2020","journal-title":"Neuro Oncol."},{"key":"10.1016\/j.bcp.2026.117724_b0010","doi-asserted-by":"crossref","DOI":"10.1016\/j.ebiom.2023.104963","article-title":"Glioblastoma vaccines: past, present, and opportunities","volume":"100","author":"Xiong","year":"2024","journal-title":"EBioMedicine"},{"key":"10.1016\/j.bcp.2026.117724_b0015","doi-asserted-by":"crossref","DOI":"10.3389\/fphar.2022.868695","article-title":"The evasion mechanisms of cancer immunity and drug intervention in the tumor microenvironment","volume":"13","author":"Kim","year":"2022","journal-title":"Front. Pharmacol."},{"issue":"12","key":"10.1016\/j.bcp.2026.117724_b0020","doi-asserted-by":"crossref","first-page":"1354","DOI":"10.1038\/s41423-024-01226-x","article-title":"Immunotherapy for glioblastoma: current state, challenges, and future perspectives","volume":"21","author":"Liu","year":"2024","journal-title":"Cell. Mol. Immunol."},{"key":"10.1016\/j.bcp.2026.117724_b0025","doi-asserted-by":"crossref","DOI":"10.1016\/j.bcp.2024.116725","article-title":"Targeting the tumor microenvironment with mesenchymal stem cells based delivery approach for efficient delivery of anticancer agents: an updated review","volume":"232","author":"Yu","year":"2025","journal-title":"Biochem. Pharmacol."},{"key":"10.1016\/j.bcp.2026.117724_b0030","doi-asserted-by":"crossref","DOI":"10.1016\/j.addr.2023.114821","article-title":"Recent progress in NIR-II fluorescence imaging-guided drug delivery for cancer theranostics","volume":"197","author":"Roy","year":"2023","journal-title":"Adv. Drug Deliv. Rev."},{"key":"10.1016\/j.bcp.2026.117724_b0035","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2023.1255611","article-title":"Immunotherapy: a promising approach for glioma treatment","volume":"14","author":"Yasinjan","year":"2023","journal-title":"Front. Immunol."},{"issue":"9","key":"10.1016\/j.bcp.2026.117724_b0040","doi-asserted-by":"crossref","first-page":"2266","DOI":"10.1158\/0008-5472.CAN-16-2310","article-title":"Cellular and molecular identity of tumor-associated macrophages in glioblastoma","volume":"77","author":"Chen","year":"2017","journal-title":"Cancer Res."},{"issue":"1","key":"10.1016\/j.bcp.2026.117724_b0045","doi-asserted-by":"crossref","first-page":"51","DOI":"10.1186\/s13073-024-01321-8","article-title":"Glioblastoma-instructed microglia transition to heterogeneous phenotypic states with phagocytic and dendritic cell-like features in patient tumors and patient-derived orthotopic xenografts","volume":"16","author":"Yabo","year":"2024","journal-title":"Genome Med."},{"issue":"1","key":"10.1016\/j.bcp.2026.117724_b0050","doi-asserted-by":"crossref","first-page":"4814","DOI":"10.1038\/s41467-022-32430-w","article-title":"Single cell spatial analysis reveals the topology of immunomodulatory purinergic signaling in glioblastoma","volume":"13","author":"Coy","year":"2022","journal-title":"Nat. Commun."},{"issue":"10","key":"10.1016\/j.bcp.2026.117724_b0055","doi-asserted-by":"crossref","first-page":"1654","DOI":"10.1038\/s41590-023-01605-y","article-title":"Kunitz-type protease inhibitor TFPI2 remodels stemness and immunosuppressive tumor microenvironment in glioblastoma","volume":"24","author":"Pang","year":"2023","journal-title":"Nat. Immunol."},{"issue":"2","key":"10.1016\/j.bcp.2026.117724_b0060","doi-asserted-by":"crossref","first-page":"170","DOI":"10.1038\/ncb3090","article-title":"Periostin secreted by glioblastoma stem cells recruits M2 tumour-associated macrophages and promotes malignant growth","volume":"17","author":"Zhou","year":"2015","journal-title":"Nat. Cell Biol."},{"issue":"5","key":"10.1016\/j.bcp.2026.117724_b0065","doi-asserted-by":"crossref","first-page":"729","DOI":"10.1038\/s41593-019-0370-y","article-title":"Control of tumor-associated macrophages and T cells in glioblastoma via AHR and CD39","volume":"22","author":"Takenaka","year":"2019","journal-title":"Nat. Neurosci."},{"issue":"1","key":"10.1016\/j.bcp.2026.117724_b0070","doi-asserted-by":"crossref","first-page":"20","DOI":"10.1038\/nn.4185","article-title":"The role of microglia and macrophages in glioma maintenance and progression","volume":"19","author":"Hambardzumyan","year":"2016","journal-title":"Nat. Neurosci."},{"issue":"19","key":"10.1016\/j.bcp.2026.117724_b0075","doi-asserted-by":"crossref","first-page":"5336","DOI":"10.1016\/j.cell.2024.07.030","article-title":"Macrophage-mediated myelin recycling fuels brain cancer malignancy","volume":"187","author":"Kloosterman","year":"2024","journal-title":"Cell"},{"key":"10.1016\/j.bcp.2026.117724_b0080","doi-asserted-by":"crossref","unstructured":"V. Governa, K.G. de Oliveira, A. B\u00e5ng-Rudenstam, S. Offer, M. Cerezo-Maga\u00f1a, J. Li, S. Beyer, M.C. Johansson, A.S. M\u00e5nsson, C. Edvardsson, F. Durmo, E. Gustafsson, A. Boukredine, P. Jeannot, K. Schmidt, E. Gezelius, J.A. Menard, R. Garza, J. Jakobsson, T. de Neergaard, P.C. Sundgren, A.M. Tiihonen, H. Haapasalo, K.J. Rautajoki, P. Nordenfelt, A. Darabi, K. Forsberg-Nilsson, A. Pietras, H. Talbot, J. Bengzon, and M. Belting, Protumoral lipid droplet-loaded macrophages are enriched in human glioblastoma and can be therapeutically targeted. Sci Transl Med. 16 (771) (2024) eadk1168, 10.1126\/scitranslmed.adk1168.","DOI":"10.1126\/scitranslmed.adk1168"},{"key":"10.1016\/j.bcp.2026.117724_b0085","article-title":"Neutrophils in glioma microenvironment: from immune function to immunotherapy","volume":"15\u20132024","author":"Sun","year":"2024","journal-title":"Front. Immunol."},{"issue":"Pt 3","key":"10.1016\/j.bcp.2026.117724_b0090","article-title":"A comprehensive review on the dynamics of protein kinase CK2 in cancer development and optimizing therapeutic strategies","volume":"280","author":"Ghani","year":"2024","journal-title":"Int. J. Biol. Macromol."},{"issue":"9","key":"10.1016\/j.bcp.2026.117724_b0095","doi-asserted-by":"crossref","first-page":"1549","DOI":"10.1016\/j.ccell.2024.08.008","article-title":"Glioblastoma induces the recruitment and differentiation of dendritic-like \u201chybrid\u201d neutrophils from skull bone marrow","volume":"42","author":"Lad","year":"2024","journal-title":"Cancer Cell"},{"key":"10.1016\/j.bcp.2026.117724_b0100","doi-asserted-by":"crossref","unstructured":"M. Gonz\u00e1lez-Tablas Pimenta, \u00c1. Otero, D.A. Arandia Guzman, D. Pascual-Argente, L. Ru\u00edz Mart\u00edn, P. Sousa-Casasnovas, A. Garc\u00eda-Martin, J.C. Roa Montes de Oca, J. Villase\u00f1or-Ledezma, L. Torres Carretero, M. Almeida, J. Ortiz, A. Nieto, A. Orfao, and M.D. Tabernero, Tumor cell and immune cell profiles in primary human glioblastoma: Impact on patient outcome. Brain Pathol. 31 (2) (2021) 365-380, 10.1111\/bpa.12927.","DOI":"10.1111\/bpa.12927"},{"key":"10.1016\/j.bcp.2026.117724_b0105","article-title":"Enhancing T cell infiltration in glioblastoma: a review article on challenges and therapeutic strategies","volume":"45","author":"Habibi","year":"2025","journal-title":"Cancer Treat. Res. Commun."},{"key":"10.1016\/j.bcp.2026.117724_b0110","doi-asserted-by":"crossref","DOI":"10.1016\/j.intimp.2024.112922","article-title":"Immunosuppressive MDSC and Treg signatures predict prognosis and therapeutic response in glioma","volume":"141","author":"Yin","year":"2024","journal-title":"Int. Immunopharmacol."},{"issue":"19","key":"10.1016\/j.bcp.2026.117724_b0115","doi-asserted-by":"crossref","first-page":"5671","DOI":"10.1158\/0008-5472.CAN-16-0144","article-title":"CCL2 produced by the glioma microenvironment is essential for the recruitment of regulatory T cells and myeloid-derived suppressor cells","volume":"76","author":"Chang","year":"2016","journal-title":"Cancer Res."},{"issue":"7","key":"10.1016\/j.bcp.2026.117724_b0120","doi-asserted-by":"crossref","DOI":"10.3390\/jcm10071367","article-title":"Checkpoint inhibitors as high-grade gliomas treatment: state of the art and future perspectives","volume":"10","author":"Persico","year":"2021","journal-title":"J. Clin. Med."},{"key":"10.1016\/j.bcp.2026.117724_b0125","doi-asserted-by":"crossref","unstructured":"R.L.Y. Ho, I.A.W. Ho, Recent advances in glioma therapy: combining vascular normalization and immune checkpoint blockade, Cancers (Basel), 13(15) (2021), 10.3390\/cancers13153686.","DOI":"10.3390\/cancers13153686"},{"key":"10.1016\/j.bcp.2026.117724_b0130","doi-asserted-by":"crossref","first-page":"526","DOI":"10.3389\/fimmu.2020.00526","article-title":"The Interactions between cancer stem cells and the innate interferon signaling pathway","volume":"11","author":"Martin-Hijano","year":"2020","journal-title":"Front. Immunol."},{"issue":"1","key":"10.1016\/j.bcp.2026.117724_b0135","doi-asserted-by":"crossref","first-page":"448","DOI":"10.1038\/s41467-018-08271-x","article-title":"FGL2 promotes tumor progression in the CNS by suppressing CD103(+) dendritic cell differentiation","volume":"10","author":"Yan","year":"2019","journal-title":"Nat. Commun."},{"issue":"7","key":"10.1016\/j.bcp.2026.117724_b0140","doi-asserted-by":"crossref","first-page":"66","DOI":"10.1007\/s12032-016-0778-0","article-title":"Malignant gliomas induce and exploit astrocytic mesenchymal-like transition by activating canonical Wnt\/\u03b2-catenin signaling","volume":"33","author":"Lu","year":"2016","journal-title":"Med. Oncol."},{"key":"10.1016\/j.bcp.2026.117724_b0145","doi-asserted-by":"crossref","DOI":"10.1016\/j.neuint.2019.104628","article-title":"Potassium and glutamate transport is impaired in scar-forming tumor-associated astrocytes","volume":"133","author":"Campbell","year":"2020","journal-title":"Neurochem. Int."},{"key":"10.1016\/j.bcp.2026.117724_b0150","doi-asserted-by":"crossref","DOI":"10.1016\/j.biopha.2020.110086","article-title":"Novel insights into astrocyte-mediated signaling of proliferation, invasion and tumor immune microenvironment in glioblastoma","volume":"126","author":"Zhang","year":"2020","journal-title":"Biomed. Pharmacother."},{"issue":"5","key":"10.1016\/j.bcp.2026.117724_b0155","doi-asserted-by":"crossref","first-page":"648","DOI":"10.1038\/s43018-023-00556-5","article-title":"GAP43-dependent mitochondria transfer from astrocytes enhances glioblastoma tumorigenicity","volume":"4","author":"Watson","year":"2023","journal-title":"Nat Cancer."},{"issue":"3","key":"10.1016\/j.bcp.2026.117724_b0160","doi-asserted-by":"crossref","DOI":"10.3892\/ijo.2022.5394","article-title":"Glioma\u2011neuronal interactions in tumor progression: mechanism, therapeutic strategies and perspectives (review)","volume":"61","author":"Hua","year":"2022","journal-title":"Int. J. Oncol."},{"issue":"7775","key":"10.1016\/j.bcp.2026.117724_b0165","doi-asserted-by":"crossref","first-page":"539","DOI":"10.1038\/s41586-019-1563-y","article-title":"Electrical and synaptic integration of glioma into neural circuits","volume":"573","author":"Venkatesh","year":"2019","journal-title":"Nature"},{"key":"10.1016\/j.bcp.2026.117724_b0170","doi-asserted-by":"crossref","DOI":"10.1016\/j.bcp.2025.117637","article-title":"Nutraceutical interventions for neuroprotection: a comprehensive review","volume":"245","author":"Ghosh","year":"2026","journal-title":"Biochem. Pharmacol."},{"key":"10.1016\/j.bcp.2026.117724_b0175","doi-asserted-by":"crossref","unstructured":"K.R. Taylor, T. Barron, A. Hui, A. Spitzer, B. Yal\u00e7in, A.E. Ivec, A.C. Geraghty, G.G. Hartmann, M. Arzt, S.M. Gillespie, Y.S. Kim, S. Maleki Jahan, H. Zhang, K. Shamardani, M. Su, L. Ni, P.P. Du, P.J. Woo, A. Silva-Torres, H.S. Venkatesh, R. Mancusi, A. Ponnuswami, S. Mulinyawe, M.B. Keough, I. Chau, R. Aziz-Bose, I. Tirosh, M.L. Suv\u00e0, and M. Monje, Glioma synapses recruit mechanisms of adaptive plasticity. Nature. 623(7986) (2023) 366-374, 10.1038\/s41586-023-06678-1.","DOI":"10.1038\/s41586-023-06678-1"},{"issue":"7673","key":"10.1016\/j.bcp.2026.117724_b0180","doi-asserted-by":"crossref","first-page":"533","DOI":"10.1038\/nature24014","article-title":"Targeting neuronal activity-regulated neuroligin-3 dependency in high-grade glioma","volume":"549","author":"Venkatesh","year":"2017","journal-title":"Nature"},{"issue":"2","key":"10.1016\/j.bcp.2026.117724_b0185","doi-asserted-by":"crossref","first-page":"390","DOI":"10.1016\/j.cell.2024.11.002","article-title":"Characterizing and targeting glioblastoma neuron-tumor networks with retrograde tracing","volume":"188","author":"Tetzlaff","year":"2025","journal-title":"Cell"},{"key":"10.1016\/j.bcp.2026.117724_b0190","doi-asserted-by":"crossref","unstructured":"J.D. Bernstock, M. Mehari, J.V. E. Gerstl, D.M. Meredith, P.A. Valdes, P. Heesen, V.S. Ambati, S. Krishna, J.A. Chen, H. Arora, B.R. Johnston, M. Negussie, K. Grieco, C. Nava Gonzales, A. Dada, A.B. Lebouille-Veldman, A. Kabir, L. Spanehl, J. Kaur, S. Oten, Y.E. Sibih, R.A. Mekary, A. Daniel, J.F. de Groot, S. Izzy, F.A. Gessler, S. Stone, O. Arnaout, Y. Lu, B.D. Choi, M.D. Hall, M.P. Mehta, Y. Odia, G.K. Friedman, E.A. Chiocca, P.P. Peruzzi, T.R. Smith, S.L. Hervey-Jumper, Gabapentinoids confer survival benefit in human glioblastoma. Nat. Commun., 16(1) (2025) 4483, 10.1038\/s41467-025-59614-4.","DOI":"10.1038\/s41467-025-59614-4"},{"issue":"5","key":"10.1016\/j.bcp.2026.117724_b0195","doi-asserted-by":"crossref","first-page":"2461","DOI":"10.1007\/s12035-020-01892-8","article-title":"Tumor development and angiogenesis in adult brain tumor: glioblastoma","volume":"57","author":"Ahir","year":"2020","journal-title":"Mol. Neurobiol."},{"issue":"11","key":"10.1016\/j.bcp.2026.117724_b0200","doi-asserted-by":"crossref","DOI":"10.3390\/ijms25116118","article-title":"Understanding the role of endothelial cells in glioblastoma: mechanisms and novel treatments","volume":"25","author":"Hovis","year":"2024","journal-title":"Int. J. Mol. Sci."},{"key":"10.1016\/j.bcp.2026.117724_b0205","doi-asserted-by":"crossref","DOI":"10.3389\/fonc.2022.947634","article-title":"Exploring the origin of the cancer stem cell niche and its role in anti-angiogenic treatment for glioblastoma","volume":"12","author":"Akindona","year":"2022","journal-title":"Front. Oncol."},{"issue":"1","key":"10.1016\/j.bcp.2026.117724_b0210","doi-asserted-by":"crossref","first-page":"44","DOI":"10.1186\/s12964-022-00854-y","article-title":"Tumor immunotherapies by immune checkpoint inhibitors (ICIs); the pros and cons","volume":"20","author":"Naimi","year":"2022","journal-title":"Cell Commun. Signal"},{"issue":"11","key":"10.1016\/j.bcp.2026.117724_b0215","doi-asserted-by":"crossref","DOI":"10.1016\/j.drudis.2024.104188","article-title":"From promise to progress: the dynamic landscape of glioblastoma immunotherapy","volume":"29","author":"Ijaz","year":"2024","journal-title":"Drug Discov. Today"},{"issue":"1","key":"10.1016\/j.bcp.2026.117724_b0220","doi-asserted-by":"crossref","first-page":"123","DOI":"10.1093\/neuonc\/noac099","article-title":"Radiotherapy combined with nivolumab or temozolomide for newly diagnosed glioblastoma with unmethylated MGMT promoter: an international randomized phase III trial","volume":"25","author":"Omuro","year":"2023","journal-title":"Neuro Oncol."},{"issue":"11","key":"10.1016\/j.bcp.2026.117724_b0225","doi-asserted-by":"crossref","first-page":"1935","DOI":"10.1093\/neuonc\/noac116","article-title":"Phase III trial of chemoradiotherapy with temozolomide plus nivolumab or placebo for newly diagnosed glioblastoma with methylated MGMT promoter","volume":"24","author":"Lim","year":"2022","journal-title":"Neuro Oncol."},{"issue":"4","key":"10.1016\/j.bcp.2026.117724_b0230","doi-asserted-by":"crossref","first-page":"1048","DOI":"10.1158\/1078-0432.CCR-20-2500","article-title":"Randomized phase II and biomarker study of pembrolizumab plus bevacizumab versus pembrolizumab alone for patients with recurrent glioblastoma","volume":"27","author":"Nayak","year":"2021","journal-title":"Clin. Cancer Res."},{"issue":"1","key":"10.1016\/j.bcp.2026.117724_b0235","doi-asserted-by":"crossref","first-page":"6938","DOI":"10.1038\/s41467-021-26940-2","article-title":"Neoadjuvant PD-1 blockade induces T cell and cDC1 activation but fails to overcome the immunosuppressive tumor associated macrophages in recurrent glioblastoma","volume":"12","author":"Lee","year":"2021","journal-title":"Nat. Commun."},{"key":"10.1016\/j.bcp.2026.117724_b0240","doi-asserted-by":"crossref","unstructured":"K. Lam, H.Y. Lin, G. Williford, C. Wathoo, N. Majd, Ivosidenib off-label use for IDH mutant gliomas: the MD Anderson cancer center real life experience, 41(16_suppl) (2023) e14022-e14022, 10.1200\/JCO.2023.41.16_suppl.e14022.","DOI":"10.1200\/JCO.2023.41.16_suppl.e14022"},{"issue":"12","key":"10.1016\/j.bcp.2026.117724_b0245","doi-asserted-by":"crossref","first-page":"2567","DOI":"10.1158\/1078-0432.CCR-21-4064","article-title":"Circulating immune cell and outcome analysis from the phase II study of PD-L1 blockade with durvalumab for newly diagnosed and recurrent glioblastoma","volume":"28","author":"Nayak","year":"2022","journal-title":"Clin. Cancer Res."},{"key":"10.1016\/j.bcp.2026.117724_b0250","doi-asserted-by":"crossref","unstructured":"S.-P.S. Weathers, C. Kamiya-Matsuoka, R.A. Harrison, D.D. Liu, S. Dervin, C. Yun, M.E. Loghin, M. Penas-Prado, N. Majd, W.K.A. Yung, B.J. O'Brien, J.F.D. Groot, Phase I\/II study to evaluate the safety and clinical efficacy of atezolizumab (atezo; aPDL1) in combination with temozolomide (TMZ) and radiation in patients with newly diagnosed glioblastoma (GBM). 38(15_suppl) (2020) 2511-2511, 10.1200\/JCO.2020.38.15_suppl.2511.","DOI":"10.1200\/JCO.2020.38.15_suppl.2511"},{"issue":"1","key":"10.1016\/j.bcp.2026.117724_b0255","doi-asserted-by":"crossref","first-page":"198","DOI":"10.1186\/s12885-020-6624-y","article-title":"a phase II open label, randomised study of ipilimumab with temozolomide versus temozolomide alone after surgery and chemoradiotherapy in patients with recently diagnosed glioblastoma: the Ipi-Glio trial protocol","volume":"20","author":"Brown","year":"2020","journal-title":"BMC Cancer"},{"issue":"6","key":"10.1016\/j.bcp.2026.117724_b0260","doi-asserted-by":"crossref","DOI":"10.1136\/jitc-2020-002296","article-title":"Intracerebral administration of CTLA-4 and PD-1 immune checkpoint blocking monoclonal antibodies in patients with recurrent glioblastoma: a phase I clinical trial","volume":"9","author":"Duerinck","year":"2021","journal-title":"J. Immunother. Cancer"},{"issue":"5","key":"10.1016\/j.bcp.2026.117724_b0265","doi-asserted-by":"crossref","first-page":"1388","DOI":"10.1111\/cas.16128","article-title":"Upregulation of HLA-II related to LAG-3(+) CD4(+) T cell infiltration is associated with patient outcome in human glioblastoma","volume":"115","author":"Guo","year":"2024","journal-title":"Cancer Sci."},{"key":"10.1016\/j.bcp.2026.117724_b0270","doi-asserted-by":"crossref","unstructured":"I. Ausejo-Mauleon, S. Labiano, D. de la Nava, V. Laspidea, M. Zalacain, L. Marrod\u00e1n, M. Garc\u00eda-Moure, M. Gonz\u00e1lez-Huarriz, I. Herv\u00e1s-Corpi\u00f3n, L. Dhandapani, S. Vicent, M. Collantes, I. Pe\u00f1uelas, O.J. Becher, M.G. Filbin, L. Jiang, J. Labelle, C.A.O. de Biagi-Junior, J. Nazarian, S. Laternser, T.N. Phoenix, J. van der Lugt, M. Kranendonk, R. Hoogendijk, S. Mueller, C. De Andrea, A.C. Anderson, E. Guruceaga, C. Koschmann, V.N. Yadav, J. G\u00e1llego P\u00e9rez-Larraya, A. Pati\u00f1o-Garc\u00eda, F. Pastor, M.M. Alonso, TIM-3 blockade in diffuse intrinsic pontine glioma models promotes tumor regression and antitumor immune memory. Cancer Cell, 41(11) (2023) 1911-1926.e8, 10.1016\/j.ccell.2023.09.001.","DOI":"10.1016\/j.ccell.2023.09.001"},{"issue":"1","key":"10.1016\/j.bcp.2026.117724_b0275","doi-asserted-by":"crossref","first-page":"1909","DOI":"10.1038\/s41467-024-46343-3","article-title":"synNotch-programmed iPSC-derived NK cells usurp TIGIT and CD73 activities for glioblastoma therapy","volume":"15","author":"Lupo","year":"2024","journal-title":"Nat. Commun."},{"key":"10.1016\/j.bcp.2026.117724_b0280","doi-asserted-by":"crossref","unstructured":"R. Lukas, S. Sachdev, P. Kumthekar, K. Dixit, S. Grimm, V. Gondi, L. Sharp, R. Lezon, D. James, M. Lesniak, R. Stupp, D. Wainwright, CTIM-12. A phase 1 trial of immunoradiotherapy with the IDO enzyme inhibitor (bms-986205) and Nivolumab in patients with newly diagnosed mgmt promoter unmethylated IDHwt glioblastoma. J. Neuro-Oncol., 23(Supplement_6) (2021) vi51-vi52, 10.1093\/neuonc\/noab196.204%.","DOI":"10.1093\/neuonc\/noab196.204"},{"issue":"2","key":"10.1016\/j.bcp.2026.117724_b0285","doi-asserted-by":"crossref","first-page":"141","DOI":"10.1023\/A:1006293606710","article-title":"Pilot study of local autologous tumor infiltrating lymphocytes for the treatment of recurrent malignant gliomas","volume":"45","author":"Quattrocchi","year":"1999","journal-title":"J. Neurooncol"},{"key":"10.1016\/j.bcp.2026.117724_b0290","doi-asserted-by":"crossref","unstructured":"Y. Yao, D. Chen, C. Tang, C. Ji, Z. Li, Q. Qian, Safety, efficacy, and biomarker analysis of response to engineered tumor-infiltrating lymphocytes secreting anti-PD-1 antibody in recurrent glioblastoma: An open-label, two-arms, phase 1 study, 41(16_suppl) (2023) 2042-2042, 10.1200\/JCO.2023.41.16_suppl.2042.","DOI":"10.1200\/JCO.2023.41.16_suppl.2042"},{"issue":"26","key":"10.1016\/j.bcp.2026.117724_b0295","doi-asserted-by":"crossref","first-page":"2561","DOI":"10.1056\/NEJMoa1610497","article-title":"Regression of glioblastoma after chimeric antigen receptor T-cell therapy","volume":"375","author":"Brown","year":"2016","journal-title":"N. Engl. J. Med."},{"issue":"4","key":"10.1016\/j.bcp.2026.117724_b0300","doi-asserted-by":"crossref","first-page":"1001","DOI":"10.1038\/s41591-024-02875-1","article-title":"Locoregional delivery of IL-13R\u03b12-targeting CAR-T cells in recurrent high-grade glioma: a phase 1 trial","volume":"30","author":"Brown","year":"2024","journal-title":"Nat. Med."},{"issue":"22","key":"10.1016\/j.bcp.2026.117724_b0305","doi-asserted-by":"crossref","first-page":"6846","DOI":"10.1158\/1078-0432.CCR-17-0890","article-title":"Epidermal growth factor receptor variant III (EGFRvIII) positivity in EGFR-amplified glioblastomas: prognostic role and comparison between primary and recurrent tumors","volume":"23","author":"Felsberg","year":"2017","journal-title":"Clin. Cancer Res."},{"issue":"14","key":"10.1016\/j.bcp.2026.117724_b0310","doi-asserted-by":"crossref","first-page":"1290","DOI":"10.1056\/NEJMoa2314390","article-title":"Intraventricular CARv3-TEAM-E T cells in recurrent glioblastoma","volume":"390","author":"Choi","year":"2024","journal-title":"N. Engl. J. Med."},{"issue":"5","key":"10.1016\/j.bcp.2026.117724_b0315","doi-asserted-by":"crossref","first-page":"1320","DOI":"10.1038\/s41591-024-02893-z","article-title":"Intrathecal bivalent CAR T cells targeting EGFR and IL13R\u03b12 in recurrent glioblastoma: phase 1 trial interim results","volume":"30","author":"Bagley","year":"2024","journal-title":"Nat. Med."},{"issue":"8","key":"10.1016\/j.bcp.2026.117724_b0320","doi-asserted-by":"crossref","first-page":"911","DOI":"10.1038\/s43018-022-00418-6","article-title":"Cancer vaccines: the next immunotherapy frontier","volume":"3","author":"Lin","year":"2022","journal-title":"Nat. Cancer."},{"issue":"25","key":"10.1016\/j.bcp.2026.117724_b0325","doi-asserted-by":"crossref","first-page":"7807","DOI":"10.7150\/thno.37194","article-title":"Peptide-based materials for cancer immunotherapy","volume":"9","author":"Zhang","year":"2019","journal-title":"Theranostics"},{"issue":"1","key":"10.1016\/j.bcp.2026.117724_b0330","doi-asserted-by":"crossref","first-page":"283","DOI":"10.1038\/s41392-023-01557-7","article-title":"Vaccine adjuvants: mechanisms and platforms","volume":"8","author":"Zhao","year":"2023","journal-title":"Signal Transduct. Target. Ther."},{"issue":"7","key":"10.1016\/j.bcp.2026.117724_b0335","doi-asserted-by":"crossref","first-page":"1453","DOI":"10.1200\/JCO.22.00996","article-title":"Phase IIa study of SurVaxM plus adjuvant temozolomide for newly diagnosed glioblastoma","volume":"41","author":"Ahluwalia","year":"2023","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.bcp.2026.117724_b0340","doi-asserted-by":"crossref","unstructured":"M.S. Ahluwalia, M.J. Ciesielski, D.A. Reardon, N.A. Butowski, R. Aiken, V. Venur, A.P. Abad, L. Mechtler, D.M. Peereboom, Y. Odia, K. Sinicrope, J.A. Boockvar, A.J. Brenner, M. Barbaro, A. Ozair, A. Belal, J.-X. Qiu, A.A. Khosla, D.M. Casucci, R.A. Fenstermaker, A multicenter, randomized controlled phase 2b trial of survivin vaccine SurVaxM plus adjuvant temozolomide for newly diagnosed glioblastoma (SURVIVE). 42(16_suppl) (2024) TPS2099-TPS2099, 10.1200\/JCO.2024.42.16_suppl.TPS2099.","DOI":"10.1200\/JCO.2024.42.16_suppl.TPS2099"},{"key":"10.1016\/j.bcp.2026.117724_b0345","doi-asserted-by":"crossref","DOI":"10.1016\/j.ebiom.2023.104963","article-title":"Glioblastoma vaccines: past, present, and opportunities","volume":"100","author":"Xiong","year":"2024","journal-title":"EBioMedicine"},{"issue":"19","key":"10.1016\/j.bcp.2026.117724_b0350","doi-asserted-by":"crossref","first-page":"4776","DOI":"10.1158\/1078-0432.CCR-16-0506","article-title":"A cancer research UK first time in human phase I trial of IMA950 (novel multipeptide therapeutic vaccine) in patients with newly diagnosed glioblastoma","volume":"22","author":"Rampling","year":"2016","journal-title":"Clin. Cancer Res."},{"issue":"4","key":"10.1016\/j.bcp.2026.117724_b0355","doi-asserted-by":"crossref","DOI":"10.3390\/cancers11040464","article-title":"Exploratory study of the effect of IMA950\/Poly-ICLC Vaccination on response to bevacizumab in relapsing high-grade glioma patients","volume":"11","author":"Boydell","year":"2019","journal-title":"Cancers (Basel)"},{"issue":"2","key":"10.1016\/j.bcp.2026.117724_b0360","doi-asserted-by":"crossref","first-page":"274","DOI":"10.1093\/neuonc\/not203","article-title":"Heat-shock protein peptide complex-96 vaccination for recurrent glioblastoma: a phase II, single-arm trial","volume":"16","author":"Bloch","year":"2014","journal-title":"Neuro Oncol."},{"issue":"14","key":"10.1016\/j.bcp.2026.117724_b0365","doi-asserted-by":"crossref","first-page":"3575","DOI":"10.1158\/1078-0432.CCR-16-1369","article-title":"Autologous heat shock protein peptide vaccination for newly diagnosed glioblastoma: impact of peripheral PD-L1 expression on response to therapy","volume":"23","author":"Bloch","year":"2017","journal-title":"Clin. Cancer Res."},{"key":"10.1016\/j.bcp.2026.117724_b0370","doi-asserted-by":"crossref","unstructured":"D.A. Reardon, S. Brem, A.S. Desai, S.J. Bagley, S.C. Kurz, M.I. De La Fuente, S. Nagpal, M.R. Welch, A. Hormigo, P. Forsyth, J. Mandell, S. Khagi, R. Aiken, T. Walbert, F. Lieberman, J. Portnow, J. Batiste, N. Carroll, A. Sylvester, P. Campbell, I. Lowy, A. Dolgoter, J. Boyer, K. Kraynyak, M.P. Morrow, T. McMullan, D.B. Weiner, J. Skolnik, LTBK-01. INO-5401 and INO-9012 delivered intramuscularly (IM) with electroporation (EP) in combination with cemiplimab (REGN2810) in newly diagnosed glioblastoma. Neuro-Oncol., 22(Supplement_2) (2020) ii237-ii237, 10.1093\/neuonc\/noaa215.988 %J Neuro-Oncology.","DOI":"10.1093\/neuonc\/noaa215.988"},{"key":"10.1016\/j.bcp.2026.117724_b0375","doi-asserted-by":"crossref","DOI":"10.3390\/cancers16071276","article-title":"Immunotherapeutic strategies for the treatment of glioblastoma: current challenges and future perspectives","volume":"16","author":"Salvato","year":"2024","journal-title":"Cancers (Basel)"},{"issue":"10","key":"10.1016\/j.bcp.2026.117724_b0380","doi-asserted-by":"crossref","first-page":"6195","DOI":"10.1021\/acs.nanolett.8b02179","article-title":"Personalized tumor RNA loaded lipid-nanoparticles prime the systemic and intratumoral milieu for response to cancer immunotherapy","volume":"18","author":"Sayour","year":"2018","journal-title":"Nano Lett."},{"key":"10.1016\/j.bcp.2026.117724_b0385","doi-asserted-by":"crossref","unstructured":"F. Iwamoto, N. Nissen, D. Reardon, D. Forst, E. Lee, T. Berthoud, C. Soare, F. Diaz-Mitoma, D. Anderson, P. Wen, N. Willumsen, M. Karsdal, A. Lassman, CTIM-27. Peripheral biomarker analysis of T cell-mediated collagen remodeling correlates with tumor responses in a phase iia trial of vaccine immunotherapeutic candidate (VBI-1901). Neuro-Oncol., 25(Supplement_5) (2023) v68-v68, 10.1093\/neuonc\/noad179.0267 %J Neuro-Oncology.","DOI":"10.1093\/neuonc\/noad179.0267"},{"issue":"1","key":"10.1016\/j.bcp.2026.117724_b0390","doi-asserted-by":"crossref","first-page":"112","DOI":"10.1001\/jamaoncol.2022.5370","article-title":"Association of autologous tumor lysate-loaded dendritic cell vaccination with extension of survival among patients with newly diagnosed and recurrent glioblastoma: a phase 3 prospective externally controlled cohort trial","volume":"9","author":"Liau","year":"2023","journal-title":"JAMA Oncol."},{"issue":"19","key":"10.1016\/j.bcp.2026.117724_b0395","doi-asserted-by":"crossref","first-page":"5799","DOI":"10.1158\/1078-0432.CCR-19-0261","article-title":"A randomized double-blind placebo-controlled phase II trial of dendritic cell vaccine ICT-107 in newly diagnosed patients with glioblastoma","volume":"25","author":"Wen","year":"2019","journal-title":"Clin. Cancer Res."},{"key":"10.1016\/j.bcp.2026.117724_b0400","doi-asserted-by":"crossref","DOI":"10.3389\/fphar.2022.1082797","article-title":"Comprehensive assessment on the applications of oncolytic viruses for cancer immunotherapy","volume":"13","author":"Omole","year":"2022","journal-title":"Front. Pharmacol."},{"issue":"6","key":"10.1016\/j.bcp.2026.117724_b0405","doi-asserted-by":"crossref","first-page":"1158","DOI":"10.3390\/v13061158","article-title":"The current landscape of oncolytic herpes simplex viruses as novel therapies for brain malignancies","volume":"13","author":"Bernstock","year":"2021","journal-title":"Viruses"},{"issue":"22","key":"10.1016\/j.bcp.2026.117724_b0410","doi-asserted-by":"crossref","first-page":"1648","DOI":"10.1038\/sj.gt.3302289","article-title":"HSV1716 injection into the brain adjacent to tumour following surgical resection of high-grade glioma: safety data and long-term survival","volume":"11","author":"Harrow","year":"2004","journal-title":"Gene Ther."},{"issue":"9","key":"10.1016\/j.bcp.2026.117724_b0415","doi-asserted-by":"crossref","first-page":"938","DOI":"10.1038\/nm0995-938","article-title":"Attenuated multi-mutated herpes simplex virus-1 for the treatment of malignant gliomas","volume":"1","author":"Mineta","year":"1995","journal-title":"Nat. Med."},{"issue":"11","key":"10.1016\/j.bcp.2026.117724_b0420","doi-asserted-by":"crossref","first-page":"6396","DOI":"10.1073\/pnas.101136398","article-title":"Oncolytic herpes simplex virus vector with enhanced MHC class I presentation and tumor cell killing","volume":"98","author":"Todo","year":"2001","journal-title":"Proc. Natl. Acad. Sci. USA"},{"issue":"8","key":"10.1016\/j.bcp.2026.117724_b0425","doi-asserted-by":"crossref","first-page":"1630","DOI":"10.1038\/s41591-022-01897-x","article-title":"Intratumoral oncolytic herpes virus G47\u0394 for residual or recurrent glioblastoma: a phase 2 trial","volume":"28","author":"Todo","year":"2022","journal-title":"Nat. Med."},{"issue":"4","key":"10.1016\/j.bcp.2026.117724_b0430","doi-asserted-by":"crossref","DOI":"10.1136\/jitc-2024-008880","article-title":"Oncolytic herpes simplex virus expressing IL-2 controls glioblastoma growth and improves survival","volume":"12","author":"Bommareddy","year":"2024","journal-title":"J. Immunother. Cancer"},{"issue":"3","key":"10.1016\/j.bcp.2026.117724_b0435","doi-asserted-by":"crossref","first-page":"208","DOI":"10.1215\/S1152851703000577","article-title":"Poliovirus receptor CD155-targeted oncolysis of glioma","volume":"6","author":"Merrill","year":"2004","journal-title":"Neuro Oncol."},{"issue":"2","key":"10.1016\/j.bcp.2026.117724_b0440","doi-asserted-by":"crossref","first-page":"150","DOI":"10.1056\/NEJMoa1716435","article-title":"Recurrent glioblastoma treated with recombinant poliovirus","volume":"379","author":"Desjardins","year":"2018","journal-title":"N. Engl. J. Med."},{"issue":"17","key":"10.1016\/j.bcp.2026.117724_b0445","doi-asserted-by":"crossref","first-page":"2389","DOI":"10.1089\/104303400750038499","article-title":"A phase III clinical evaluation of herpes simplex virus type 1 thymidine kinase and ganciclovir gene therapy as an adjuvant to surgical resection and radiation in adults with previously untreated glioblastoma multiforme","volume":"11","author":"Rainov","year":"2000","journal-title":"Hum. Gene Ther."},{"issue":"12","key":"10.1016\/j.bcp.2026.117724_b0450","doi-asserted-by":"crossref","first-page":"1939","DOI":"10.1001\/jamaoncol.2020.3161","article-title":"Effect of vocimagene amiretrorepvec in combination with flucytosine vs standard of care on survival following tumor resection in patients with recurrent high-grade glioma: a randomized clinical trial","volume":"6","author":"Cloughesy","year":"2020","journal-title":"JAMA Oncol."},{"issue":"505","key":"10.1016\/j.bcp.2026.117724_b0455","doi-asserted-by":"crossref","DOI":"10.1126\/scitranslmed.aaw5680","article-title":"Regulatable interleukin-12 gene therapy in patients with recurrent high-grade glioma: results of a phase 1 trial","volume":"11","author":"Chiocca","year":"2019","journal-title":"Sci. Transl. Med."},{"key":"10.1016\/j.bcp.2026.117724_b0460","doi-asserted-by":"crossref","unstructured":"A.J. Brenner, K.B. Peters, J. Vredenburgh, F. Bokstein, D.T. Blumenthal, S. Yust-Katz, I. Peretz, B. Oberman, L.S. Freedman, B.M. Ellingson, T.F. Cloughesy, N. Sher, Y.C. Cohen, N. Lowenton-Spier, T. Rachmilewitz Minei, N. Yakov, I. Mendel, E. Breitbart, P.Y. Wen, Safety and efficacy of VB-111, an anticancer gene therapy, in patients with recurrent glioblastoma: results of a phase I\/II study. Neuro Oncol., 22(5) (2020) 694-704, 10.1093\/neuonc\/noz231.","DOI":"10.1093\/neuonc\/noz231"},{"key":"10.1016\/j.bcp.2026.117724_b0465","unstructured":"T.F. Cloughesy, A. Brenner, J.F. de Groot, N.A. Butowski, L. Zach, J.L. Campian, B.M. Ellingson, L.S. Freedman, Y.C. Cohen, N. Lowenton-Spier, T. Rachmilewitz Minei, S. Fain Shmueli, P.Y. Wen, a randomized controlled phase III study of VB-111 combined with bevacizumab vs bevacizumab monotherapy in patients with recurrent glioblastoma (GLOBE). Neuro Oncol., 22(5) (2020) 705-717, 10.1093\/neuonc\/noz232."},{"issue":"23","key":"10.1016\/j.bcp.2026.117724_b0470","doi-asserted-by":"crossref","DOI":"10.3390\/ijms232314613","article-title":"Microglia-derived olfactomedin-like 3 is a potent angiogenic factor in primary mouse brain endothelial cells: a novel target for glioblastoma","volume":"23","author":"Joseph","year":"2022","journal-title":"Int. J. Mol. Sci."},{"issue":"22","key":"10.1016\/j.bcp.2026.117724_b0475","doi-asserted-by":"crossref","DOI":"10.1172\/JCI178628","article-title":"Dual targeting macrophages and microglia is a therapeutic vulnerability in models of PTEN-deficient glioblastoma","volume":"134","author":"Liu","year":"2024","journal-title":"J. Clin. Invest."},{"issue":"4","key":"10.1016\/j.bcp.2026.117724_b0480","doi-asserted-by":"crossref","first-page":"584","DOI":"10.1093\/neuonc\/noab228","article-title":"Glioblastoma genetic drivers dictate the function of tumor-associated macrophages\/microglia and responses to CSF1R inhibition","volume":"24","author":"Rao","year":"2022","journal-title":"Neuro Oncol."},{"issue":"9","key":"10.1016\/j.bcp.2026.117724_b0485","doi-asserted-by":"crossref","first-page":"1273","DOI":"10.1038\/s43018-023-00598-9","article-title":"Siglec-9 acts as an immune-checkpoint molecule on macrophages in glioblastoma, restricting T-cell priming and immunotherapy response","volume":"4","author":"Mei","year":"2023","journal-title":"Nat. Cancer."},{"key":"10.1016\/j.bcp.2026.117724_b0490","doi-asserted-by":"crossref","unstructured":"C. Dobersalske, L. Rauschenbach, Y. Hua, C. Berliner, A. Steinbach, A. Gr\u00fcneboom, K.D. Kokkaliaris, D.H. Heiland, P. Berger, S. Langer, C.L. Tan, M. Stenzel, S. Landolsi, F. Weber, M. Darkwah Oppong, R.A. Werner, H. Gull, T. Schr\u00f6der, T. Linsenmann, A.K. Buck, M. Gunzer, M. Stuschke, K. Keyvani, M. Forsting, M. Glas, J. Kipnis, D.A. Steindler, H.C. Reinhardt, E.W. Green, M. Platten, A. Tasdogan, K. Herrmann, F. Rambow, I. Cima, U. Sure, B. Scheffler, Cranioencephalic functional lymphoid units in glioblastoma. Nat Med., 30(10) (2024) 2947-2956, 10.1038\/s41591-024-03152-x.","DOI":"10.1038\/s41591-024-03152-x"},{"issue":"10","key":"10.1016\/j.bcp.2026.117724_b0495","doi-asserted-by":"crossref","DOI":"10.1172\/JCI186034","article-title":"targeting legumain-mediated cell-cell interaction sensitizes glioblastoma to immunotherapy in preclinical models","volume":"135","author":"Pang","year":"2025","journal-title":"J. Clin. Invest."},{"issue":"10","key":"10.1016\/j.bcp.2026.117724_b0500","doi-asserted-by":"crossref","first-page":"1418","DOI":"10.1038\/s43018-023-00626-8","article-title":"A designer peptide against the EAG2-Kv\u03b22 potassium channel targets the interaction of cancer cells and neurons to treat glioblastoma","volume":"4","author":"Dong","year":"2023","journal-title":"Nat. Cancer."},{"issue":"6","key":"10.1016\/j.bcp.2026.117724_b0505","doi-asserted-by":"crossref","first-page":"1119","DOI":"10.1111\/bpa.12887","article-title":"Epithelioid glioblastoma with microglia features: potential for novel therapy","volume":"30","author":"Nakagomi","year":"2020","journal-title":"Brain Pathol."},{"key":"10.1016\/j.bcp.2026.117724_b0510","doi-asserted-by":"crossref","unstructured":"E. Bouffet, J.R. Hansford, M.L. Garr\u00e8, J. Hara, A. Plant-Fox, I. Aerts, F. Locatelli, J. van der Lugt, L. Papusha, F. Sahm, U. Tabori, K.J. Cohen, R.J. Packer, O. Witt, L. Sandalic, A. Bento Pereira da Silva, M. Russo, D.R. Hargrave, Dabrafenib plus trametinib in pediatric glioma with BRAF V600 mutations, N Engl. J. Med., 389(12) (2023) 1108-1120, 10.1056\/NEJMoa2303815.","DOI":"10.1056\/NEJMoa2303815"},{"key":"10.1016\/j.bcp.2026.117724_b0515","doi-asserted-by":"crossref","DOI":"10.1016\/j.bcp.2025.116789","article-title":"Nanoengineered immune check point inhibitors delivery for targeted brain cancer treatment: current status and future perspectives","volume":"233","author":"Liu","year":"2025","journal-title":"Biochem. Pharmacol."},{"issue":"2","key":"10.1016\/j.bcp.2026.117724_b0520","doi-asserted-by":"crossref","first-page":"184","DOI":"10.1093\/neuonc\/nox175","article-title":"Is the blood-brain barrier really disrupted in all glioblastomas? A critical assessment of existing clinical data","volume":"20","author":"Sarkaria","year":"2018","journal-title":"Neuro Oncol."},{"issue":"37","key":"10.1016\/j.bcp.2026.117724_b0525","doi-asserted-by":"crossref","first-page":"33008","DOI":"10.1021\/acsnano.5c11629","article-title":"Piezodynamic therapy: unleashing mechanical energy and featuristic next generation therapeutic paradigms for glioblastoma","volume":"19","author":"Muhammad","year":"2025","journal-title":"ACS Nano"},{"issue":"6","key":"10.1016\/j.bcp.2026.117724_b0530","doi-asserted-by":"crossref","first-page":"522","DOI":"10.1097\/CCO.0000000000000990","article-title":"Unveiling the enigma of the blood-brain barrier in glioblastoma: current advances from preclinical and clinical studies","volume":"35","author":"Ahmed","year":"2023","journal-title":"Curr. Opin. Oncol."},{"issue":"48","key":"10.1016\/j.bcp.2026.117724_b0535","doi-asserted-by":"crossref","DOI":"10.1002\/smll.202510697","article-title":"NIR-II fluorescence and magnetic resonance imaging-guided efficient piezodynamic therapy of subcutaneous glioblastoma with a biomimetic nanoplatform containing defect-engineered piezoelectric shell and downconversion nanocore","volume":"21","author":"Ullah","year":"2025","journal-title":"Small"},{"key":"10.1016\/j.bcp.2026.117724_b0540","article-title":"The immunosuppressive microenvironment and immunotherapy in human glioblastoma","volume":"13","author":"Zhang","year":"2022","journal-title":"Front. Immunol."},{"key":"10.1016\/j.bcp.2026.117724_b0545","doi-asserted-by":"crossref","first-page":"737","DOI":"10.3389\/fimmu.2020.00737","article-title":"The emerging role of myeloid-derived suppressor cells in the glioma immune suppressive microenvironment","volume":"11","author":"Mi","year":"2020","journal-title":"Front. Immunol."},{"issue":"1","key":"10.1016\/j.bcp.2026.117724_b0550","doi-asserted-by":"crossref","DOI":"10.1136\/jitc-2019-000379","article-title":"T lymphocyte-targeted immune checkpoint modulation in glioma","volume":"8","author":"Kelly","year":"2020","journal-title":"J. Immunother. Cancer"},{"issue":"1","key":"10.1016\/j.bcp.2026.117724_b0555","doi-asserted-by":"crossref","first-page":"16","DOI":"10.1038\/s41416-018-0333-1","article-title":"Immunosuppression mediated by myeloid-derived suppressor cells (MDSCs) during tumour progression","volume":"120","author":"Groth","year":"2019","journal-title":"Br. J. Cancer"},{"issue":"8","key":"10.1016\/j.bcp.2026.117724_b0560","doi-asserted-by":"crossref","first-page":"1591","DOI":"10.1007\/s11011-024-01414-8","article-title":"Genomic, epigenomic and transcriptomic landscape of glioblastoma","volume":"39","author":"Dakal","year":"2024","journal-title":"Metab. Brain Dis."},{"issue":"27","key":"10.1016\/j.bcp.2026.117724_b0565","doi-asserted-by":"crossref","first-page":"2155","DOI":"10.1038\/s41388-023-02738-y","article-title":"Glioblastoma heterogeneity at single cell resolution","volume":"42","author":"Eisenbarth","year":"2023","journal-title":"Oncogene"},{"issue":"3","key":"10.1016\/j.bcp.2026.117724_b0570","doi-asserted-by":"crossref","first-page":"223","DOI":"10.1016\/j.trecan.2020.01.009","article-title":"Glioblastoma stem cells: driving resilience through chaos","volume":"6","author":"Prager","year":"2020","journal-title":"Trends Cancer."},{"key":"10.1016\/j.bcp.2026.117724_b0575","doi-asserted-by":"crossref","DOI":"10.3389\/fncel.2021.663092","article-title":"Mechanisms of invasion in glioblastoma: extracellular matrix, Ca (2+) signaling, and glutamate","volume":"15","author":"So","year":"2021","journal-title":"Front. Cell. Neurosci."},{"issue":"7528","key":"10.1016\/j.bcp.2026.117724_b0580","doi-asserted-by":"crossref","first-page":"572","DOI":"10.1038\/nature14001","article-title":"predicting immunogenic tumour mutations by combining mass spectrometry and exome sequencing","volume":"515","author":"Yadav","year":"2014","journal-title":"Nature"},{"issue":"1","key":"10.1016\/j.bcp.2026.117724_b0585","doi-asserted-by":"crossref","first-page":"7","DOI":"10.1093\/neuonc\/nop009","article-title":"TGF-beta downregulates the activating receptor NKG2D on NK cells and CD8+ T cells in glioma patients","volume":"12","author":"Crane","year":"2010","journal-title":"Neuro Oncol."},{"issue":"6","key":"10.1016\/j.bcp.2026.117724_b0590","doi-asserted-by":"crossref","first-page":"868","DOI":"10.1016\/j.ccell.2019.05.003","article-title":"Symbiotic macrophage-glioma cell interactions reveal synthetic lethality in PTEN-Null glioma","volume":"35","author":"Chen","year":"2019","journal-title":"Cancer Cell"},{"key":"10.1016\/j.bcp.2026.117724_b0595","doi-asserted-by":"crossref","DOI":"10.1016\/j.biopha.2025.118669","article-title":"Neurologic complications of immune checkpoint inhibitors: a comprehensive review","volume":"192","author":"Lashkajani","year":"2025","journal-title":"Biomed. Pharmacother."},{"key":"10.1016\/j.bcp.2026.117724_b0600","article-title":"Temozolomide treatment induces HMGB1 to promote the formation of glioma stem cells via the TLR2\/NEAT1\/Wnt pathway in glioblastoma","volume":"9","author":"Gao","year":"2021","journal-title":"Front. Cell Dev. Biol."},{"issue":"Pt 1","key":"10.1016\/j.bcp.2026.117724_b0605","article-title":"A modern approach to glioblastoma using temozolomide and nanoparticles carrier drug: a standard care of combination therapy and treatment","volume":"242","author":"Rahman","year":"2025","journal-title":"Biochem. Pharmacol."},{"issue":"Suppl 1","key":"10.1016\/j.bcp.2026.117724_b0610","article-title":"581 final analysis of 2-THE-TOP: a phase 2 study of TTFields (Optune) plus pembrolizumab plus maintenance temozolomide (TMZ) in patients with newly diagnosed glioblastoma","volume":"11","author":"Tran","year":"2023","journal-title":"J. Immunother. Cancer"},{"issue":"4","key":"10.1016\/j.bcp.2026.117724_b0615","article-title":"Progress update on STING agonists as vaccine adjuvants","volume":"13","author":"Shen","year":"2025","journal-title":"Vaccines (Basel)"},{"issue":"3","key":"10.1016\/j.bcp.2026.117724_b0620","doi-asserted-by":"crossref","first-page":"433","DOI":"10.1093\/neuonc\/noac239","article-title":"exploiting radiation immunostimulatory effects to improve glioblastoma outcome","volume":"25","author":"Awada","year":"2023","journal-title":"Neuro Oncol."},{"issue":"4","key":"10.1016\/j.bcp.2026.117724_b0625","doi-asserted-by":"crossref","first-page":"677","DOI":"10.1093\/neuonc\/noaa260","article-title":"Hypofractionated stereotactic re-irradiation with pembrolizumab and bevacizumab in patients with recurrent high-grade gliomas: results from a phase I study","volume":"23","author":"Sahebjam","year":"2021","journal-title":"Neuro Oncol."},{"issue":"6","key":"10.1016\/j.bcp.2026.117724_b0630","doi-asserted-by":"crossref","first-page":"1370","DOI":"10.1038\/s41591-023-02347-y","article-title":"Oncolytic DNX-2401 virotherapy plus pembrolizumab in recurrent glioblastoma: a phase 1\/2 trial","volume":"29","author":"Nassiri","year":"2023","journal-title":"Nat. Med."},{"issue":"2","key":"10.1016\/j.bcp.2026.117724_b0635","doi-asserted-by":"crossref","first-page":"225","DOI":"10.1093\/neuonc\/nox139","article-title":"Preclinical investigation of combined gene-mediated cytotoxic immunotherapy and immune checkpoint blockade in glioblastoma","volume":"20","author":"Speranza","year":"2018","journal-title":"Neuro Oncol."},{"key":"10.1016\/j.bcp.2026.117724_b0640","doi-asserted-by":"crossref","unstructured":"A. Schmidts, A.A. Srivastava, R. Ramapriyan, S.R. Bailey, A.A. Bouffard, D.P. Cahill, B.S. Carter, W.T. Curry, G.P. Dunn, M.J. Frigault, E.R. Gerstner, J.Y. Ghannam, M.C. Kann, R.C. Larson, M.B. Leick, B.V. Nahed, L.G. Richardson, I. Scarf\u00f2, J. Sun, H. Wakimoto, M.V. Maus, B.D. Choi, Tandem chimeric antigen receptor (CAR) T cells targeting EGFRvIII and IL-13R\u03b12 are effective against heterogeneous glioblastoma. Neurooncol. Adv., 5(1) (2023) vdac185, 10.1093\/noajnl\/vdac185.","DOI":"10.1093\/noajnl\/vdac185"},{"issue":"17","key":"10.1016\/j.bcp.2026.117724_b0645","doi-asserted-by":"crossref","first-page":"11165","DOI":"10.1021\/acsnano.4c00050","article-title":"Enhancing glioblastoma immunotherapy with integrated chimeric antigen receptor T cells through the re-education of tumor-associated microglia and macrophages","volume":"18","author":"Zhu","year":"2024","journal-title":"ACS Nano"},{"key":"10.1016\/j.bcp.2026.117724_b0650","doi-asserted-by":"crossref","DOI":"10.1002\/adtp.202400217","article-title":"Combinatory immunotherapy for glioblastoma treatment","volume":"7","author":"Ijaz","year":"2024","journal-title":"Adv. Therap."},{"issue":"6","key":"10.1016\/j.bcp.2026.117724_b0655","doi-asserted-by":"crossref","first-page":"616","DOI":"10.1016\/j.jpha.2023.04.012","article-title":"Combination immunotherapy of glioblastoma with dendritic cell cancer vaccines, anti-PD-1 and poly I:C","volume":"13","author":"Zhu","year":"2023","journal-title":"J. Pharm. Anal."},{"issue":"2","key":"10.1016\/j.bcp.2026.117724_b0660","doi-asserted-by":"crossref","DOI":"10.1172\/JCI163452","article-title":"Understanding and therapeutically exploiting cGAS\/STING signaling in glioblastoma","volume":"134","author":"Low","year":"2024","journal-title":"J. Clin. Invest."},{"key":"10.1016\/j.bcp.2026.117724_b0665","article-title":"Exosomal ncRNAs in liquid biopsy: a new paradigm for early cancer diagnosis and monitoring","volume":"15\u20132025","author":"Ghani","year":"2025","journal-title":"Front. Oncol."},{"issue":"10","key":"10.1016\/j.bcp.2026.117724_b0670","doi-asserted-by":"crossref","first-page":"1455","DOI":"10.1038\/s43018-023-00620-0","article-title":"Myeloid-specific KDM6B inhibition sensitizes glioblastoma to PD1 blockade","volume":"4","author":"Goswami","year":"2023","journal-title":"Nat Cancer."},{"issue":"6","key":"10.1016\/j.bcp.2026.117724_b0675","doi-asserted-by":"crossref","first-page":"770","DOI":"10.1158\/2326-6066.CIR-21-0559","article-title":"Circadian regulator CLOCK drives immunosuppression in glioblastoma","volume":"10","author":"Xuan","year":"2022","journal-title":"Cancer Immunol. Res."},{"key":"10.1016\/j.bcp.2026.117724_b0680","doi-asserted-by":"crossref","DOI":"10.1016\/j.ebiom.2023.104963","article-title":"Glioblastoma vaccines: past, present, and opportunities","volume":"100","author":"Xiong","year":"2024","journal-title":"EBioMedicine"},{"key":"10.1016\/j.bcp.2026.117724_b0685","doi-asserted-by":"crossref","unstructured":"H.W. Sim, L. Wachsmuth, E.H. Barnes, S. Yip, E.S. Koh, M. Hall, R. Jennens, D.M. Ashley, R.G. Verhaak, A.B. Heimberger, M.A. Rosenthal, E.J. Hovey, B.M. Ellingson, A. Tognela, H.K. Gan, H. Wheeler, M. Back, K.L. McDonald, A. Long, K. Cuff, S. Begbie, C. Gedye, A. Mislang, H. Le, M.O. Johnson, B.Y. Kong, J.R. Simes, Z. Lwin, M. Khasraw, NUTMEG: a randomized phase II study of nivolumab and temozolomide versus temozolomide alone in newly diagnosed older patients with glioblastoma. Neurooncol. Adv., 5(1) (2023) vdad124, 10.1093\/noajnl\/vdad124.","DOI":"10.1093\/noajnl\/vdad124"},{"issue":"7","key":"10.1016\/j.bcp.2026.117724_b0690","doi-asserted-by":"crossref","first-page":"1003","DOI":"10.1001\/jamaoncol.2020.1024","article-title":"Effect of nivolumab vs bevacizumab in patients with recurrent glioblastoma: the checkmate 143 phase 3 randomized clinical trial","volume":"6","author":"Reardon","year":"2020","journal-title":"JAMA Oncol."},{"key":"10.1016\/j.bcp.2026.117724_b0695","doi-asserted-by":"crossref","unstructured":"D. Tran, A. Ghiaseddin, D. Chen, S. Le, 581 Final analysis of 2-THE-TOP: a phase 2 study of TTFields (Optune) plus pembrolizumab plus maintenance temozolomide (TMZ) in patients with newly diagnosed glioblastoma, 11 (2023) 661-661, 10.1136\/jitc-2023-SITC2023.0581.","DOI":"10.1136\/jitc-2023-SITC2023.0581"},{"key":"10.1016\/j.bcp.2026.117724_b0700","doi-asserted-by":"crossref","unstructured":"D.A. Reardon, T.M. Kim, J.S. Frenel, M. Simonelli, J. Lopez, D.S. Subramaniam, L.L. Siu, H. Wang, S. Krishnan, K.J.C. Stein, Treatment with pembrolizumab in programmed death ligand 1\u2013positive recurrent glioblastoma: Results from the multicohort phase 1 KEYNOTE\u2010028 trial. 127(10) (2021) 1620-1629.","DOI":"10.1002\/cncr.33378"},{"issue":"1","key":"10.1016\/j.bcp.2026.117724_b0705","article-title":"Avelumab in newly diagnosed glioblastoma","volume":"3","author":"Jacques","year":"2021","journal-title":"Neurooncol. Adv."},{"key":"10.1016\/j.bcp.2026.117724_b0710","doi-asserted-by":"crossref","unstructured":"G. Awada, L. Ben Salama, J. De Cremer, J.K. Schwarze, L. Fischbuch, L. Seynaeve, S. Du Four, A.-M. Vanbinst, A. Michotte, H. Everaert, A. Rogiers, P. Theuns, J. Duerinck, B. Neyns, Axitinib plus avelumab in the treatment of recurrent glioblastoma: a stratified, open-label, single-center phase 2 clinical trial (GliAvAx). J. ImmunoTherapy Cancer, 8(2) (2020) e001146, 10.1136\/jitc-2020-001146.","DOI":"10.1136\/jitc-2020-001146"},{"issue":"8","key":"10.1016\/j.bcp.2026.117724_b0715","doi-asserted-by":"crossref","first-page":"1318","DOI":"10.1093\/neuonc\/noac024","article-title":"Off-the-shelf, steroid-resistant, IL13R\u03b12-specific CAR T cells for treatment of glioblastoma","volume":"24","author":"Brown","year":"2022","journal-title":"Neuro Oncol."},{"key":"10.1016\/j.bcp.2026.117724_b0720","article-title":"PD1 expression in EGFRvIII-directed CAR T cell infusion product for glioblastoma is associated with clinical response","volume":"13","author":"Tang","year":"2022","journal-title":"Front. Immunol."},{"issue":"7","key":"10.1016\/j.bcp.2026.117724_b0725","doi-asserted-by":"crossref","first-page":"1586","DOI":"10.1158\/1078-0432.CCR-18-1140","article-title":"Rindopepimut with bevacizumab for patients with relapsed EGFRvIII-expressing glioblastoma (ReACT): results of a double-blind randomized phase II trial","volume":"26","author":"Reardon","year":"2020","journal-title":"Clin. Cancer Res."},{"key":"10.1016\/j.bcp.2026.117724_b0730","doi-asserted-by":"crossref","unstructured":"O. Bloch, Q. Shi, S.K. Anderson, M. Knopp, J. Raizer, J. Clarke, A. Waziri, H. Colman, J. Bruce, J.J. Olson, J. Schwerkoske, A. Parsa, J. Uhm, P. Kumthekar, E. Galanis, I. Parney, ATIM-14. ALLIANCE A071101: a phase ii randomized trial comparing the efficacy of heat shock protein peptide complex-96 (HSPPC-96) vaccine given with bevacizumab versus bevacizumab alone in the treatment of surgically resectable recurrent glioblastoma. Neuro-Oncol., 19(suppl_6) (2017) vi29-vi29, 10.1093\/neuonc\/nox168.110 %J Neuro-Oncology.","DOI":"10.1093\/neuonc\/nox168.110"},{"key":"10.1016\/j.bcp.2026.117724_b0735","doi-asserted-by":"crossref","unstructured":"D. Migliorini, V. Dutoit, M. Allard, N. Grandjean Hallez, E. Marinari, V. Widmer, G. Philippin, F. Corlazzoli, R. Gustave, M. Kreutzfeldt, N. Blazek, J. Wasem, A. Hottinger, A. Koka, S. Momjian, A. Lobrinus, D. Merkler, M.I. Vargas, P.R. Walker, A. Patrikidou, P.Y. Dietrich, Phase I\/II trial testing safety and immunogenicity of the multipeptide IMA950\/poly-ICLC vaccine in newly diagnosed adult malignant astrocytoma patients. Neuro Oncol., 21(7) (2019) 923-933, 10.1093\/neuonc\/noz040.","DOI":"10.1093\/neuonc\/noz040"},{"issue":"4","key":"10.1016\/j.bcp.2026.117724_b0740","doi-asserted-by":"crossref","first-page":"689","DOI":"10.1158\/1078-0432.CCR-21-2867","article-title":"A phase I study of autologous dendritic cell vaccine pulsed with allogeneic stem-like cell line lysate in patients with newly diagnosed or recurrent glioblastoma","volume":"28","author":"Hu","year":"2022","journal-title":"Clin. Cancer Res."},{"issue":"1","key":"10.1016\/j.bcp.2026.117724_b0745","doi-asserted-by":"crossref","first-page":"4119","DOI":"10.1038\/s41467-022-31262-y","article-title":"A phase I\/II study of triple-mutated oncolytic herpes virus G47\u0394 in patients with progressive glioblastoma","volume":"13","author":"Todo","year":"2022","journal-title":"Nat. Commun."},{"issue":"9","key":"10.1016\/j.bcp.2026.117724_b0750","doi-asserted-by":"crossref","first-page":"1042","DOI":"10.1016\/S1470-2045(23)00347-9","article-title":"Combined cytotoxic and immune-stimulatory gene therapy for primary adult high-grade glioma: a phase 1, first-in-human trial","volume":"24","author":"Umemura","year":"2023","journal-title":"Lancet Oncol."}],"container-title":["Biochemical Pharmacology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0006295226000559?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0006295226000559?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,5,6]],"date-time":"2026-05-06T08:36:58Z","timestamp":1778056618000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0006295226000559"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,4]]},"references-count":150,"alternative-id":["S0006295226000559"],"URL":"https:\/\/doi.org\/10.1016\/j.bcp.2026.117724","relation":{},"ISSN":["0006-2952"],"issn-type":[{"value":"0006-2952","type":"print"}],"subject":[],"published":{"date-parts":[[2026,4]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Unraveling the glioblastoma (GBM) tumor microenvironment: future perspective on targeted immunotherapy","name":"articletitle","label":"Article Title"},{"value":"Biochemical Pharmacology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.bcp.2026.117724","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 Published by Elsevier Inc.","name":"copyright","label":"Copyright"}],"article-number":"117724"}}